Italia markets close in 5 hours 40 minutes

Genetic Technologies Limited (0A4N.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,0600-0,4900 (-31,61%)
Al 03:09PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente1,5500
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume271.016
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,09
Rapporto PE (ttm)N/D
EPS (ttm)-0,6000
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

    MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical & Scientific Affairs and GTG in the US) and Adjunct Professor Charles Siles Health (Executive Director and founder of Siles Health). A/Prof. Charles Siles, Obstetrician and Gynaecologist operates nine (9) clinics across Vic

  • GlobeNewswire

    Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

    MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating the performance of the geneType ovarian cancer test. This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Canc

  • GlobeNewswire

    Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

    MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23). Q1 FY23 Highlights: Revenue from customers of A$1.93 million for the quarter, up 375% from prior corresponding period (Q1 FY22), highlighting commercial progress with revenues anchoring from GTG’s